Approval · Notice of Compliance 11875 · 2010
LITHMAX: Notice of Compliance 11875
Issued November 19, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11875
- Date
- November 19, 2010
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Antimanic agent
- Canadian reference product
- DURALITH (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LITHMAX | 02266695 | Marketed |
Medicinal ingredients
- LITHIUM CARBONATE 300 MG per TAB